Antibodies
IVD
RUO
MetaGene is a supplier of antibodies from reputable USA manufacturers.
​
Biocare Medical’s vast portfolio of antibodies meets your clinical and research laboratory needs. Choose from a wide variety of offerings within each antibody from concentrate, ready to use predilute or pre-optimized antibodies built to operate on various automated instruments such as the ONCORE Pro, intelliPATH FLX, Leica Bond, or Roche Benchmark Ultra.
Biocare is your solution for top-performing, high-quality antibodies.
​
Check out our Top Antibodies
SOX10
The SOX10 protein is widely expressed in normal human tissues including melanocytes and breast tissue. It is also an important marker in malignant tumors such as melanoma, breast carcinoma, gliomas and benign tumors such as schwannomas. SOX10 antibody has been shown to be expressed in 97-100% of desmoplastic and spindle cell melanomas and was also shown to be expressed in 100% of nevi. The majority of oligodendrogliomas but also a large percentage of astrocytomas and poorly differentiated glioblastomas have also been shown to express SOX10. PATENT PENDING.
​
Download the datasheet:
p63
p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. p63 is detected in prostatic basal cells in normal prostate; however, it is negative in malignant tumors of the prostate gland. Thus p63 antibody may be a valuable tool in the differential diagnosis of benign and malignant tumors of prostate gland and can be used in a panel of antibodies such as HMW CK [34ßE12], PSA and PSAP. p63 may play a significant role in prostate development by maintaining a prostate stem cell population. Striated muscle staining may be observed with p63.
​
Download the datasheet:
PRAME [EPR20330]
PRAME (preferentially expressed antigen in melanoma) is located on chromosome 22q11.22 and encodes a 509 amino acid protein. PRAME is an autosomal cancer-testis antigen (CTA) gene. PRAME is expressed in melanoma, various nonmelanocytic malignant neoplasms, including nonsmall cell lung cancer, breast carcinoma, renal cell carcinoma, ovarian carcinoma, leukemia, synovial sarcoma, and myxoid liposarcoma. Normal healthy tissues are not known to express PRAME except for testis, ovary, placenta, adrenals, and endometrium.(1,2)
​
​​
1. Zhang W, Barter CJ, Eng KH, et al. PRAME expression and promoter hypermethylation in epithelial ovarian cancer. Oncotarget 2016 Jul; 7(29): 45352-45369. 2. Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018 Nov; 42(11): 1456–1465.
​
Download the datasheet:
p40
The mouse monoclonal antibody p40 [BC28] recognizes an epitope unique to the p40 protein and may have applications in cases where p63 has traditionally been used. p63 [4A4] recognizes both the p63 and p40 proteins. As a result, p63 suffers from specificity limitations due to reactivity in a subset of lung adenocarcinomas (ADC). In contrast, p40 is selectively expressed in lung Squamous cell carcinoma (SqCC), offering an opportunity for improved specificity. p40 antibody (M) [BC28] recognizes an epitope unique to p40, which may result in diminished reactivity in lung ADC and increased specificity. Studies have supported routine use of p40 as an alternative for p63. In contrast to the rabbit polyclonal p40, p40 [BC28] does not stain macrophages.
​
Download the datasheet:
Treponema Pallidum
​Spirochete (Treponema pallidum) is the causative agent of syphilis. Spirochete can now be successfully localized with a treponema pallidum antibody using immunohistochemical techniques in formalin-fixed, paraffin-embedded (FFPE) tissue. In the past, localization of the spirochete agent was achieved with silver stains such as Steiner’s and/or Warthin-Starry. The spirochete antibody consists of a rabbit purified IgG fraction that is highly specific. Treponema pallidum antibody also cross-reacts with burgdorferi (Lyme disease).
​
Download the datasheet:
NKX3.1
NKX3.1 is a protein found in humans and is encoded by the NKX3.1 gene located on chromosome 8. The homeodomain containing transcription factor NKX3A is a putative prostate tumor suppressor that is expressed in a largely prostate-specific and androgen-regulated manner. NKX3.1 protein has been found to be positive in the vast majority of primary prostatic adenocarcinomas. A recent study showed that NKX3.1 staining was highly sensitive and specific for high-grade prostatic adenocarcinomas. The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, and 94.2% (65/69 cores positive) for PSA. The specificity of NKX3.1 was 99.7% (1/349) in various cancers. NKX3.1 stains nuclei in both normal and prostate cancer, thus providing a robust stain that is easy-to-interpret, similar to other transcription factors such as TTF-1 or CDX2.
​
Download the datasheet:
Cytokeratin 14
This antibody reacts with a human intermediate filament protein of 50 kDa, known as Cytokeratin 14 antibody. Studies have shown that it can be used to distinguish stratified epithelial cells from simple epithelial cells. In neoplastic cells, CK14 may be a useful marker in the differential diagnosis of squamous cell carcinoma from other epithelial tumors. Recent studies also indicate that CK14 expression in breast cancer corresponded with poor clinical outcome and that CK14 may have diagnostic value in the sub-classification of NSCLC.
​
Download the datasheet:
p16 INK4a [BC42] IVD
p16 antibody: p16 INK4a is a tumor suppressor protein involved in the pathogenesis of a variety of malignancies. It is a specific inhibitor of cdk4/cdk6. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers (1). Although the frequency of p16 INK4a abnormalities is higher in tumor-derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas (2).
​
1. LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res. 2014 Feb; 12(2):167-83.
2. Mahajan A. Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol. 2016 May; 51:64-74.
Download the datasheet:
.jpg)
.jpg)
Need a
top-performing antibody?
Trial a free Biocare Medical antibody today.